Press Release

Adamas Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

March 1, 2021 at 4:04 PM EST

EMERYVILLE, Calif.--(BUSINESS WIRE)--Mar. 1, 2021-- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the closing of its previously announced underwritten public offering of 12,500,000 shares of its common stock, plus the exercise in full by the underwriters of their option to purchase an additional 1,875,000 shares, at a price to the public of $4.40 per share. The estimated net proceeds of the offering to Adamas, after deducting underwriting discounts and commissions and other offering expenses, are expected to be $59.2 million.

SVB Leerink and William Blair acted as joint bookrunning managers for the offering. JMP Securities acted as lead manager for the offering.

The securities described above were offered by Adamas pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC"). The final prospectus supplement and accompanying prospectus related to this offering were filed with the SEC and are available on the SEC's website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained, from: SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808 7525, ext. 6105, or by email at syndicate@svbleerink.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, telephone: 1-800-621-0687, or by email: prospectus@williamblair.com.

About Adamas

At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.

Source: Adamas Pharmaceuticals, Inc.

Media:
Sarah Mathieson
Vice President, Corporate Communications
510-450-3528
smathieson@adamaspharma.com

Investors:
Peter Vozzo
Managing Director
Westwicke/ICR
443-213-0505
peter.vozzo@westwicke.com

Source: Adamas Pharmaceuticals, Inc.